Shots:
- Sebela Pharmaceuticals has entered into an agreement granting Organon exclusive global rights to Miudella, a hormone-free copper intrauterine device (IUD) contraceptive
- As per the deal, Sebela will receive $27.5M at closing & ~$505M in sales-based milestone payments, with tiered net sales-based double-digit royalties
- Miudella was approved by the US FDA in Feb 2025, for prevention of pregnancy in females of reproductive potential for ~3yrs.; it is not yet commercially available & features a flexible frame with a fully preloaded inserter
Ref: Businesswire | Image: Sebela & Organon | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
